Amylee Martin1, Akshitha Thatiparthi2, Jeffrey Liu3, Jashin J Wu4. 1. Ms. Martin is with the University of California School of Medicine in Riverside, California. 2. Ms. Thatiparthi is with the Western University of Health Sciences in Pomona, California. 3. Mr. Liu is with the Keck School of Medicine, University of Southern California, in Los Angeles, California. 4. Dr. Wu is with the Dermatology Research and Education Foundation, Irvine, California.
Abstract
Objective: Although biologics are highly effective in the treatment of psoriasis, some patients consistently fail monotherapy. For these patients, combination therapy is commonly employed. However, evidence-based recommendations for combination therapy in the treatment of psoriasis with interleukin-17 (IL-17) inhibitors are currently lacking. Therefore, we aimed to conduct a systematic review of existing literature discussing the efficacy and safety of IL-17 inhibitors in combination with other therapeutic modalities in the treatment of psoriasis. Methods of Literature Search: By way of a search of PubMed, Cochrane, and Web of Science databases in March 2021, we identified peer-reviewed articles with data on the safety and/or efficacy of IL-17 inhibitor combination therapies in adults with psoriasis and/or psoriatic arthritis (PsA). A modified version of the 2011 Oxford Centre for Evidence-Based Medicine Scheme was utilized for assessing study quality. Results: Twenty-four articles with a total of 3,154 patients met inclusion/exclusion criteria. These articles comprised six post-hoc/subgroup analyses of randomized controlled trials (RCTs), four uncontrolled clinical trials, three case series, and 11 case reports that provided data on IL-17 inhibitor therapy in combination with conventional disease-modifying antirheumatic drugs (cDMARDs), apremilast, acitretin, topical therapy, phototherapy, and/or medications for comorbid diseases. Limitations: Our results are limited by the lack of data from RCTs. Conclusion: Although cDMARDs are often used in psoriasis combination therapies, the current literature suggests concomitant cDMARDs with IL-17 inhibitor therapy provides no added benefit compared to IL-17 inhibitor monotherapy. However, IL-17 inhibitor in combination with apremilast or acitretin shows efficacy and safety in case series/reports and may allow for a reduction in medication dosing and/or frequency, thereby minimizing costs and adverse events. Future RCTs investigating IL-17 inhibitor therapy in combination with acitretin or apremilast are warranted.
Objective: Although biologics are highly effective in the treatment of psoriasis, some patients consistently fail monotherapy. For these patients, combination therapy is commonly employed. However, evidence-based recommendations for combination therapy in the treatment of psoriasis with interleukin-17 (IL-17) inhibitors are currently lacking. Therefore, we aimed to conduct a systematic review of existing literature discussing the efficacy and safety of IL-17 inhibitors in combination with other therapeutic modalities in the treatment of psoriasis. Methods of Literature Search: By way of a search of PubMed, Cochrane, and Web of Science databases in March 2021, we identified peer-reviewed articles with data on the safety and/or efficacy of IL-17 inhibitor combination therapies in adults with psoriasis and/or psoriatic arthritis (PsA). A modified version of the 2011 Oxford Centre for Evidence-Based Medicine Scheme was utilized for assessing study quality. Results: Twenty-four articles with a total of 3,154 patients met inclusion/exclusion criteria. These articles comprised six post-hoc/subgroup analyses of randomized controlled trials (RCTs), four uncontrolled clinical trials, three case series, and 11 case reports that provided data on IL-17 inhibitor therapy in combination with conventional disease-modifying antirheumatic drugs (cDMARDs), apremilast, acitretin, topical therapy, phototherapy, and/or medications for comorbid diseases. Limitations: Our results are limited by the lack of data from RCTs. Conclusion: Although cDMARDs are often used in psoriasis combination therapies, the current literature suggests concomitant cDMARDs with IL-17 inhibitor therapy provides no added benefit compared to IL-17 inhibitor monotherapy. However, IL-17 inhibitor in combination with apremilast or acitretin shows efficacy and safety in case series/reports and may allow for a reduction in medication dosing and/or frequency, thereby minimizing costs and adverse events. Future RCTs investigating IL-17 inhibitor therapy in combination with acitretin or apremilast are warranted.
Authors: Steven R Feldman; Jingchuan Zhang; Diane J Martinez; Lorena Lopez-Gonzalez; Elizabeth Hoit Marchlewicz; George Shrady; Alan M Mendelsohn; Yang Zhao Journal: J Dermatolog Treat Date: 2019-12-08 Impact factor: 3.359
Authors: Paul R Mangan; Linhui Julie Su; Victoria Jenny; Andrea L Tatum; Caryn Picarillo; Stacey Skala; Noah Ditto; Zheng Lin; XiaoXia Yang; Pete Z Cotter; David J Shuster; Yunling Song; Virna Borowski; Rochelle L Thomas; Elizabeth M Heimrich; Brigitte Devaux; Ruchira Das Gupta; Irvith Carvajal; Kim W McIntyre; Jenny Xie; Qihong Zhao; Mary Struthers; Luisa M Salter-Cid Journal: J Pharmacol Exp Ther Date: 2015-05-26 Impact factor: 4.030
Authors: Iain B McInnes; Philip J Mease; Bruce Kirkham; Arthur Kavanaugh; Christopher T Ritchlin; Proton Rahman; Désirée van der Heijde; Robert Landewé; Philip G Conaghan; Alice B Gottlieb; Hanno Richards; Luminita Pricop; Gregory Ligozio; Manmath Patekar; Shephard Mpofu Journal: Lancet Date: 2015-06-28 Impact factor: 79.321
Authors: A B Gottlieb; R G Langley; B E Strober; K A Papp; P Klekotka; K Creamer; E H Z Thompson; M Hooper; G Kricorian Journal: Br J Dermatol Date: 2012-09 Impact factor: 9.302
Authors: Désirée van der Heijde; Robert B Landewé; Philip J Mease; Iain B McInnes; Philip G Conaghan; Luminita Pricop; Greg Ligozio; Hanno B Richards; Shephard Mpofu Journal: Arthritis Rheumatol Date: 2016-08 Impact factor: 10.995
Authors: Philip J Mease; Mark C Genovese; Michael E Weinblatt; Paul M Peloso; Kun Chen; Ahmed A Othman; Yihan Li; Heikki T Mansikka; Amit Khatri; Neil Wishart; John Liu Journal: Arthritis Rheumatol Date: 2018-11 Impact factor: 10.995
Authors: Benjamin Lockshin; Angel Cronin; Ryan W Harrison; Robert R McLean; Laura Anatale-Tardiff; Russel Burge; Baojin Zhu; William N Malatestinic; Bilal Atiya; Mwangi J Murage; Gaia Gallo; Bruce Strober; Abby Van Voorhees Journal: Dermatol Ther Date: 2021-02-15 Impact factor: 2.851